|
|||||
|
|
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma |
|
| Authors: | Franç oise Denoyelle,Nicolas Leboulanger,Odile Enjolras,Gilles Roger,Eré a-Noë l Garabedian |
| Affiliation: | a Armand-Trousseau Children Hospital, Pediatric ENT Department, AP-HP, 75012 Paris, France b UPMC Univ. Paris VI, France c INSERM U-587 Paris, France d Armand-Trousseau Children Hospital, Maxillo-Facial and Plastic Surgery Department, AP-HP, 75012 Paris, France |
| Abstract: | There are recent reports of effective treatment of cutaneous hemangiomas with Propranolol. The current study aims to assess efficacy of systemic Propranolol for subglottic hemangiomas and to discuss its place among the other available therapies. We report 2 infants with subglottic hemangiomas, which were resistant to other established medical treatments. One infant presented with PHACES association, the other with widespread cutaneous congenital hemangiomas. Both were subsequently treated with systemic Propranolol. Both patients’ subglottic hemangiomas responded dramatically to systemic Propranolol. No side effects of the therapy occurred, and a safety protocol previously designed for Propranolol prescribed for other indications was applied to our patients. Propranolol appears to be an effective treatment for subglottic hemangiomas and should now be used as a first-line treatment in subglottic hemangiomas when intervention is required. |
| Keywords: | Subglottic hemangioma Propranolol Children |
| 本文献已被 ScienceDirect 等数据库收录！ | |